In patients with advanced triple negative breast cancer, the combination of a CSF-1 monoclonal antibody with gemcitabine and carboplatin showed comparable anti-tumor activity and progression-free survival compared to gemcitabine and carboplatin alone [65]. This evidence concerns the gene CSF1 and neoplasm.